Özet:

Objective: Chronic kidney disease (CKD) is an inflammatory process. Serum proinflammatory cytokines are known to be ten times higher in patients with CKD when compared to normal population. Monocyte/High density lipoprotein (HDL) cholesterol ratio (MHR) have been shown to be a new marker of inflammation and claimed that, it may be used to predict cardiovascular events in patients with CKD. This cross-sectional study aimed to compare monocyte / HDL cholesterol ratio in patients treated with hemodialysis and peritoneal dialysis. Methods: Files of patients who have been followed up with end stage renal disease (ESRD) and have peritoneal dialysis or hemodialysis therapy in Nephrology Clinic of our hospital have been retrospectively examined. Patients were divided into two groups regarding renal replacement treatment type. Monocyte / HDL cholesterol ratio was compared between groups. IBM SPSS Statistics 22.0 (IBM Corp., NY, USA) packaged software and appropriate statistical methods were used to analyse data. Results: Monocyte / HDL cholesterol ratio was significantly higher in patients treated with hemodialysis (p= 0.028). HDL cholesterol levels were significantly higher in peritoneal dialysis group (p= 0.046). Total cholesterol, LDL cholesterol, triglyceride and VLDL cholesterol have been ascertained to be similar in both patient groups (p> 0.05). The high sensitivity CRP and sedimentation levels have been detected to be similar within the groups (p> 0.05). Conclusion: This is the first study evaluating the monocyte/HDL cholesterol ratio among renal replacement therapy modalities in our literature review. In this study, it has been shown that monocyte/HDL cholesterol ratio were statistically higher in patients having hemodialysis than in the ones followed up with peritoneal dialysis. According to these results, it may be considered that peritoneal dialysis may be associated with less systemic inflammation than hemodialysis.

Anahtar Kelimeler: